| Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease FA Boros, R Maszlag-Török, L Vécsei, P Klivényi Brain research 1730, 146672, 2020 | 46 | 2020 |
| Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases FA Boros, Z Bohár, L Vécsei Mutation Research/Reviews in Mutation Research 776, 32-45, 2018 | 41 | 2018 |
| Immunomodulatory effects of genetic alterations affecting the kynurenine pathway FA Boros, L Vécsei Frontiers in Immunology 10, 465487, 2019 | 40 | 2019 |
| Gene variants and expression changes of SIRT1 and SIRT6 in peripheral blood are associated with Parkinson’s disease R Maszlag-Török, FA Boros, L Vécsei, P Klivényi Scientific reports 11 (1), 10677, 2021 | 18 | 2021 |
| Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs F Boros, L Vécsei Expert Opinion on Investigational Drugs 29 (11), 1223-1247, 2020 | 18 | 2020 |
| Indoleamine 2, 3-dioxygenase as a novel therapeutic target for Huntington’s disease FA Boros, P Klivényi, J Toldi, L Vécsei Expert opinion on therapeutic targets 23 (1), 39-51, 2019 | 18 | 2019 |
| NEAT1 on the Field of Parkinson’s Disease: Offense, Defense, or a Player on the Bench? FA Boros, L Vécsei, P Klivényi Journal of Parkinson's disease 11 (1), 123-138, 2021 | 17 | 2021 |
| From Lysosomal Storage Disorders to Parkinson’s Disease–Challenges and Opportunities R Mächtel, FA Boros, JP Dobert, P Arnold, F Zunke Journal of Molecular Biology 435 (12), 167932, 2023 | 10 | 2023 |
| The effect of physical stimuli on the expression level of key elements in mitochondrial biogenesis A Salamon, R Torok, E Sumegi, F Boros, ZG Pesei, MF Molnar, G Veres, ... Neuroscience Letters 698, 13-18, 2019 | 8 | 2019 |
| Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models A Drobny, FA Boros, D Balta, S Prieto Huarcaya, D Caylioglu, N Qazi, ... Translational neurodegeneration 12 (1), 31, 2023 | 7 | 2023 |
| Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson’s disease patients FA Boros, R Török, E Vágvölgyi-Sümegi, ZG Pesei, P Klivényi, L Vécsei Neuroscience Letters 706, 140-145, 2019 | 6 | 2019 |
| Tryptophan 2, 3-dioxygenase, a novel therapeutic target for Parkinson’s disease FA Boros, L Vécsei Expert Opinion on Therapeutic Targets 25 (10), 877-888, 2021 | 5 | 2021 |
| Cerebellar predominant increase in mRNA expression levels of Sirt1 and Sirt3 isoforms in a transgenic mouse model of Huntington’s disease A Salamon, R Maszlag-Török, G Veres, FA Boros, E Vágvölgyi-Sümegi, ... Neurochemical Research 45, 2072-2081, 2020 | 5 | 2020 |
| Spinocerebellar Ataxia in a Hungarian Female Patient with a Novel Variant of Unknown Significance in the CCDC88C Gene FA Boros, L Szpisjak, R Bozó, E Kelemen, D Zádori, A Salamon, J Danis, ... International Journal of Molecular Sciences 24 (3), 2617, 2023 | 4 | 2023 |
| Relationships of Ischemic Stroke Occurrence and Outcome with Gene Variants Encoding Enzymes of Tryptophan Metabolism FA Boros, R Maszlag-Török, M Szűcs, Á Annus, P Klivényi, L Vécsei Biomedicines 9 (10), 1441, 2021 | 1 | 2021 |
| Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples D Saarela, P Lis, S Gomes, RS Nirujogi, W Dong, E Rawat, S Glendinning, ... bioRxiv, 2024.05. 17.594681, 2024 | | 2024 |
| A Parkinson-kór genetikai háttere FA Boros, P Klivényi NEUROLÓGIAI PRAXIS 4 (1), 7-8, 2021 | | 2021 |
| Of PARK Genes and IncRNAS–Possible Molecular Mechanisms Behind Parkinson’s Disease FA Boros PQDT-Global, 2020 | | 2020 |
| Nampt Receptor FA Boros, L Vécsei | | |
